These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Scheja A; Hellmer G; Wollheim FA; Akesson A Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562 [TBL] [Abstract][Full Text] [Related]
9. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. O'Reilly D; Taylor L; el-Hadidy K; Jayson MI Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis. Scheja A; Akesson A; Hørslev-Petersen K Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489 [TBL] [Abstract][Full Text] [Related]
11. Plasma urotensin II levels in primary Raynaud's phenomenon and systemic sclerosis. Gözel N; Karataş A; Yardım M; Kınacı MS; Ulu R; Demircan F; Kılınç F; Öz B; Dönder E; Aydın S; Koca SS Turk J Med Sci; 2017 Dec; 47(6):1687-1692. PubMed ID: 29306224 [TBL] [Abstract][Full Text] [Related]
12. Cold-induced coronary Raynaud's phenomenon in patients with systemic sclerosis. Lekakis J; Mavrikakis M; Emmanuel M; Prassopoulos V; Papazoglou S; Papamichael C; Moulopoulou D; Kostamis P; Stamatelopoulos S; Moulopoulos S Clin Exp Rheumatol; 1998; 16(2):135-40. PubMed ID: 9536388 [TBL] [Abstract][Full Text] [Related]
13. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study. Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Diot E; Diot P; Valat C; Boissinot E; Asquier E; Lemarie E; Guilmot JL Eur Respir J; 1995 Sep; 8(9):1559-65. PubMed ID: 8575585 [TBL] [Abstract][Full Text] [Related]
15. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043 [TBL] [Abstract][Full Text] [Related]
16. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon. Biondi ML; Marasini B; Bianchi E; Agostoni A Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197 [TBL] [Abstract][Full Text] [Related]
17. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Kahaleh MB; Osborn I; LeRoy EC Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927 [TBL] [Abstract][Full Text] [Related]
18. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis. Goodfield MJ; Rowell NR Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617 [TBL] [Abstract][Full Text] [Related]